Diabetes Res Clin Pract 213:111745 Svensson AM, Toll A, Lebrec J, Miftaraj M, Franzn S, Eliasson B (2021) Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden
Are there any contraindications or drug interactions I should know about before starting either medication
There are no branded injectable products like Ozempic, Mounjaro, Wegovy, or Zepbound, no microdose plans, and no oral compounded tablets or drops
The article on the study results published in the journal Merits noted that this finding is consistent with other studies, and that CoH is an important factor in increasing employee engagement in wellness programming
4 The primary endpoint of SURPASS-2 was change in HbA1c from baseline to 40 weeks